Fig. 3
From: Clinical development of photodynamic agents and therapeutic applications
Chemical structure of clinically approved or under-clinical developing photosensitizing agents. a) Porfimer sodium (Photofrin®), b) Temoporfin (Foscan®), c) Motexafin lutetium and Motexafin gadolinium, d) Palladium bacteriopheophorbide, e) Purlytin®, f) Verteporfin (Visudyne®), g) Talaporfin (Laserphyrin®)